CACNA1G
ENSG00000006283
Target class
Ion channel
Chromosome
17
Approved drugs
12
Clinical candidates (approved and in development)
17
- Approved drugs
- 12
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 17
- Chemical probe available
- Yes
- Target name
- CACNA1G
- Gene name
- Calcium voltage-gated channel subunit alpha1 G
- Gene symbol
- CACNA1G
- Protein name
- Voltage-dependent T-type calcium channel subunit alpha-1G (Cav3.1c) (NBR13) (Voltage-gated calcium channel subunit alpha Cav3.1)
- Cav3.1
- NBR13
- Gene biotype
- Protein coding
- Gene family
- Calcium voltage-gated channel alpha1 subunits
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 26
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 32.6
- Tissue specificity (Gini)
- 0.754
- Tissue specificity (tau)
- 0.927
- KEGG gene identifiers
- hsa:8913
- Protein interaction confidence
- 0.815551
- Protein interaction partners
- 49
- R-HSA-419037
- R-HSA-445355
- End position
- 50627474
- Start position
- 50560715
- Chromosome
- 17
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein . Cytoplasm .
- Acrosome
- Cytosol
- Equatorial segment
- Nuclear bodies
- Nucleoplasm
- Perinuclear theca
Publication evidence
- PubMed 26715324
- Tissue specificity (tau)
- 0.927266
- Expression inequality (Gini)
- 0.753615
Expression in transcripts per million
- Brain - Cerebellum
- 32.6
- Cervix - Ectocervix
- 19.38
- Cervix - Endocervix
- 16.99
- Brain - Cortex
- 11.53
- Brain - Cerebellar Hemisphere
- 9.98
Expression in transcripts per million
- Brain - Cerebellum32.6
- Cervix - Ectocervix19.38
- Cervix - Endocervix16.99
- Brain - Cortex11.53
- Brain - Cerebellar Hemisphere9.98
- Brain - Frontal Cortex (BA9)8.88
- Ovary7.41
- Brain - Hypothalamus6.78
- Vagina6.07
- Fallopian Tube5.65
- Brain - Anterior cingulate cortex (BA24)4.29
- Uterus2.99
- Brain - Substantia nigra2.32
- Heart - Atrial Appendage2.08
- Brain - Amygdala2.04
- Adipose - Visceral (Omentum)1.96
- Prostate1.6
- Skin - Not Sun Exposed (Suprapubic)1.36
- Testis1.26
- Brain - Caudate (basal ganglia)1.2
- Skin - Sun Exposed (Lower leg)1.11
- Breast - Mammary Tissue1.09
- Brain - Hippocampus1.09
- Brain - Spinal cord (cervical c-1)1.07
- Brain - Putamen (basal ganglia)1.06
And 29 more, listed on the interactive page.
- GO:0042391
- GO:0070509
- GO:0070588
- GO:0005737
- GO:0005886
- GO:0005891
- GO:0005245
- GO:0008332
- GO:0097110
Related records
Trials (1,035)
- 'Fix the Dysfunction' Concept for Mechanism-based Pharmacological Treatment of Neuropathic Pain by Drug
- [S,S]-Reboxetine Add-On Trial
- 12-Week Efficacy And Safety Of Pregabalin In Treating Restless Legs Syndrome (RLS) Subjects
- 6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)
- 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fasting Conditions
- A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
- A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
- A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
- A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury
- A 2-part Study to Assess Local Tolerability, Safety and Pharmacokinetics of Ceftaroline in Healthy Subjects
- A 2-part Trial to Learn More About How BAY1817080 Works, How Safe it is, and What the Right Dose is for Participants With Diabetic Neuropathic Pain
- A 28-Day Polysomnographic Study of Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance
- A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough
- A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
- A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
- A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment
- A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects
Drugs (20)
- Apinocaltamide Voltage-gated T-type calcium channel blocker
- Atagabalin Voltage-gated calcium channel modulator
- Bepridil Voltage-gated calcium channel blocker
- Bepridil hydrochloride Voltage-gated calcium channel blocker
- Ethosuximide Voltage-gated T-type calcium channel blocker
- Gabapentin Voltage-gated calcium channel modulator
- Gabapentin enacarbil Voltage-gated calcium channel modulator
- Imagabalin Voltage-gated calcium channel modulator
- Methsuximide Voltage-gated T-type calcium channel blocker
- Mibefradil Voltage-gated T-type calcium channel blocker
- Mibefradil dihydrochloride Voltage-gated T-type calcium channel blocker
- Paramethadione Voltage-gated T-type calcium channel blocker
- Phensuximide Voltage-gated T-type calcium channel blocker
- Phloroglucinol Voltage-gated calcium channel blocker
- Pregabalin Voltage-gated calcium channel modulator
- Suloctidil Voltage-gated calcium channel blocker
- Suvecaltamide Voltage-gated T-type calcium channel modulator
- Terodiline Voltage-gated calcium channel blocker
- Terodiline hydrochloride Voltage-gated calcium channel blocker
- Trimethadione Voltage-gated T-type calcium channel blocker